Objective: Prophylactic treatment with the antidepressant citalopram in patients with head and neck (HN) cancer could prevent depression and improve quality of life.
Design: Prospective, randomized, placebo-controlled trial.
Setting: Academic medical center.
Patients: Thirty-six subjects were initially randomized; 23 completed the study.
Interventions: Subjects received either 40 mg of citalopram or matching placebo for 12 weeks and a final visit at 16 weeks.
W. M. Lydiatt, D. Denman, W. J. Burke. S032 Randomized Placebo-Controlled Trial of Citalopram Demonstrating Depression Prevention During Treatment for HN Cancer. Arch Otolaryngol Head Neck Surg. 2006;132(8):845. doi:10.1001/archotol.132.8.845-a